Business & EconomyHealth
Moderna Stock Nearly Triples on Cancer Vaccine Trial
Moderna shares surged 177% after its personalized mRNA cancer vaccine met Phase 3 endpoints in melanoma, marking a historic milestone for cancer treatment.
—6 min read
Tag
#Merck
4 articles
HealthBusiness
Moderna Surges After mRNA Cancer Treatment Passes Trial
Moderna and Merck announce their mRNA-based cancer vaccine intismeran met key endpoints in a Phase 3 melanoma trial, sending Moderna shares up over 120%.
—6 min read
Health and Medicine
FDA Approves Merck's Lipfendra, First Oral Cholesterol Pill
FDA approves Merck's Lipfendra (enlicitide), the first oral PCSK9 inhibitor that lowers LDL cholesterol by up to 59%, far surpassing statins.
—5 min read
HealthMedical Research
mRNA Cancer Vaccine Slashes Melanoma Recurrence by 49%
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
—4 min read